Advertisement
Drug update

Dulaglutide: a once-weekly GLP-1 receptor agonist for type 2 diabetes

KIRSTEN E. NEAL, GREGORY R. FULCHER

Figures

© AFRICA STUDIO/STOCK.ADOBE.COM
© AFRICA STUDIO/STOCK.ADOBE.COM

Abstract

The recent PBS listing of dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that is injected weekly, makes it a realistic choice for the treatment of selected patients with type 2 diabetes. What do clinicians need to know about dulaglutide?

Article Extract

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that requires only once-weekly administration and has been shown to be an effective glucose-lowering agent for patients with type 2 diabetes. Its recent PBS listing makes it a realistic therapeutic choice for many patients. This article summarises what clinicians need to know about dulaglutide and its use in patients with type 2 diabetes.

Figures

© AFRICA STUDIO/STOCK.ADOBE.COM
© AFRICA STUDIO/STOCK.ADOBE.COM